Literature DB >> 26285070

Gender-specific Effects of Treatment with Lifestyle, Metformin or Sulfonylurea on Glycemic Control and Body Weight: A German Multicenter Analysis on 9 108 Patients.

M Schütt1, A Zimmermann2, R Hood3, M Hummel4, J Seufert5, E Siegel6, A Tytko7, R W Holl8.   

Abstract

Effects of diabetes treatment are strongly connected to individual factors, but the relevant role of gender has not been addressed so far. This observational study evaluates whether monotherapy with lifestyle, metformin or sulfonylurea has gender-specific effects on glycemic control and/or body weight. Data of 9 108 patients with type 2 diabetes from 129 German diabetes centers were assessed by a standardized, prospective, computer-based diabetes care and outcome documentation system (DPV-Wiss-database; age 63.1±12.8 years, diabetes duration 5.7±7.4 years, HbA1c 55±17.7 mmol/mol [7.2±1.6%], BMI 30.6±6.1 kg/m(2), 49.3% female patients). Antidiabetic concepts included lifestyle intervention (n=5,787), metformin (n=2,180), sulfonylurea (n=943) or other antidiabetic drugs (n=198), respectively. HbA1c and body weight were compared before and after a stable monotherapeutical period of 0.8±0.4 years. Women had a significantly higher reduction of body weight after treatment with lifestyle (women-0.8±0.1 vs. men-0.2±0.1 kg; p<0.05), metformin (women-1.8±0.2 vs. men-1.2±0.2 kg; p<0.05) or sulfonylurea drugs (women-0.9±0.2 vs. men - 0.1±0.2 kg; p<0.05), whereas men displayed significantly higher HbA1c-reductions after treatment with lifestyle (women-6.9±0.2 mmol/mol [- 0.6±0.02%] vs. men-7.5±0.2 mmol/mol [0.7±0.02%]; p<0.05) and metformin only (women-6.3±0.3 mmol/mol [- 0.6±0.03%] vs. men - 7.4±0.3 mmol/mol [- 0.7±0.03%]; p<0.05). No differences were seen for sulfonylurea monotherapy concerning the HbA1c-reduction (women - 5.6±0.5 mmol/mol [- 0.5±0.05%] vs. men-6.4±0.4 mmol/mol [- 0.6±0.04%]; p=0.196). In summary, antidiabetic treatment concepts might result in gender-specific effects on body weight and HbA1c. Gender might therefore represent another important factor in the context of an individualized treatment management of type 2 diabetes. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26285070     DOI: 10.1055/s-0035-1559608

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  10 in total

1.  [Which patients from routine care use the new insulin analogue glargine U300 compared to patients with glargine U100 : A multicenter analysis of 14,123 patients with insulin glargine from die diabetes registries DPV and DIVE].

Authors:  Barbara Bohn; Peter Bramlage; Christian Wagner; Matthias Kaltheuner; Reinhard Welp; Stefan Sziegoleit; Artur Zimmermann; Hans Martin Reuter; Michael Hummel; Jörg Gloyer; Reinhard W Holl; Thomas Danne
Journal:  Wien Med Wochenschr       Date:  2017-08-21

2.  Sex- and Gender-Based Pharmacological Response to Drugs.

Authors:  Franck Mauvais-Jarvis; Heiner K Berthold; Ilaria Campesi; Juan-Jesus Carrero; Santosh Dakal; Flavia Franconi; Ioanna Gouni-Berthold; Mark L Heiman; Alexandra Kautzky-Willer; Sabra L Klein; Anne Murphy; Vera Regitz-Zagrosek; Karen Reue; Joshua B Rubin
Journal:  Pharmacol Rev       Date:  2021-04       Impact factor: 25.468

3.  Are adverse drug reactions to anti-diabetic drugs more common in patients whose treatment do not adhere to diabetes management clinical guidelines? Comments on a study report.

Authors:  Zahra Rezaie; Maryam Taghizadeh-Ghehi; Aarefeh Jafarzadeh Kohneloo
Journal:  Eur J Clin Pharmacol       Date:  2021-04-03       Impact factor: 2.953

4.  Patient characteristics associated with improvement in glycemic control following addition of an oral antidiabetic drug to DPP-4 inhibitor monotherapy in Japanese patients with type 2 diabetes mellitus (JDDM 60).

Authors:  Koichi Kawai; Jun-Ichi Eiki; Azuma Kanatsuka; Shinobu Motohashi; Akira Wakana; Ai Hayashi; Kristy Iglay; Katsuya Yamazaki; Shigeru Tokita; Hiroshi Maegawa
Journal:  Diabetol Int       Date:  2021-07-15

5.  Sex and age differences in the achievement of control targets in patients with type 2 diabetes: results from a population-based study in a South European region.

Authors:  K Cambra; A Galbete; L Forga; O Lecea; M J Ariz; C Moreno-Iribas; F Aizpuru; B Ibañez
Journal:  BMC Fam Pract       Date:  2016-10-12       Impact factor: 2.497

6.  Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry.

Authors:  Peter Bramlage; Tobias Bluhmki; Holger Fleischmann; Matthias Kaltheuner; Jan Beyersmann; Reinhard W Holl; Thomas Danne
Journal:  BMJ Open Diabetes Res Care       Date:  2017-01-25

7.  Use of Spontaneous Reporting Systems to Detect Host-Medication Interactions: Sex Differences in Oral Anti-Diabetic Drug-Associated Myocardial Infarction.

Authors:  Shi-Heng Wang; Wei J Chen; Le-Yin Hsu; Kuo-Liong Chien; Chi-Shin Wu
Journal:  J Am Heart Assoc       Date:  2018-11-20       Impact factor: 5.501

8.  Factors associated with improvement in waist-to-height ratio among newly diagnosed type 2 diabetes patients treated with acarbose or metformin: A randomized clinical trial study.

Authors:  Lu-Lu Song; Xin Wang; Zhao-Jun Yang; Xiao-Mu Kong; Xiao-Ping Chen; Bo Zhang; Wen-Ying Yang
Journal:  World J Diabetes       Date:  2020-11-15

9.  Predictors of treatment failure during the first year in newly diagnosed type 2 diabetes patients: a retrospective, observational study.

Authors:  Hon-Ke Sia; Chew-Teng Kor; Shih-Te Tu; Pei-Yung Liao; Yu-Chia Chang
Journal:  PeerJ       Date:  2021-03-02       Impact factor: 2.984

10.  Genetic and Phenotypic Factors Affecting Glycemic Response to Metformin Therapy in Patients with Type 2 Diabetes Mellitus.

Authors:  Yulia A Nasykhova; Yury A Barbitoff; Ziravard N Tonyan; Maria M Danilova; Ivan A Nevzorov; Tatiana M Komandresova; Anastasiia A Mikhailova; Tatiana V Vasilieva; Olga B Glavnova; Maria I Yarmolinskaya; Evgenia I Sluchanko; Andrey S Glotov
Journal:  Genes (Basel)       Date:  2022-07-23       Impact factor: 4.141

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.